(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 December 2006 (14.12.2006)

PCT

(10) International Publication Number
WO 2006/132460 A1

(51) International Patent Classification:
A61K 31/519 (2006.01)

(21) International Application Number:
PCT/KR2005/003526

(22) International Filing Date: 21 October 2005 (21.10.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10-2005-0050033 10 June 2005 (10.06.2005) KR

(71) Applicant *(for all designated States except US)*: **DONG-A PHARMACEUTICAL.CO., LTD.** [KR/KR]; 252 Yongdu-dong Dongdaemun-ku, Seoul 130-072 (KR).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **CHOI, Seul Min** [KR/KR]; #944-1712 Lotte Apt. Yeongtong-dong, Yeongtong-ku Suwon-si, Kyunggi-do 443-470 (KR). **AHN, Byoung Ok** [KR/KR]; #102-201 Baemeuru-Mael 555 Yeongmun-ri, Pogok-myeon Yongin-si, Kyunggi-do 449-813 (KR). **YOO, Moohi** [KR/KR]; #5-801, Woosung 3cha Apt Gaepo 1dong Kangnam-ku, Seoul 135-241 (KR).

(74) Agent: **LEE, Won-Hee**; 8th Fl. Sung-ji Heights II 642-16, Yoksam-dong Kangnam-ku, Seoul 135-080 (KR).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) **Title:** AGENT FOR THE PREVENTION AND TREATMENT OF LIVER DISEASES CONTAINING PYRAZOLOPYRIMIDINE DERIVATIVE



(57) **Abstract:** The present invention relates to the pharmaceutical compositionfor prevention and treatment of liver diseases containing pyrazolopyrimidine derivative as an active ingredient. According to the present invention, pyrazolopyrimidine derivative has an excellent effect on inhibiting collagen synthesis in hepatic stellate cellsand acts directly on the portal vein. Particularly, it may increase the diameter and the amount of blood flow of the portal vein, and finally decrease the pressure thereof. Therefore, pyrazolopyrimidine derivative can be used advantageously for prevention and treatment of hepatic fibrosis, liver cirrhosis caused by hepatic fibrosis, portal hypertension and various complications caused by portal hypertension. In addition, pyrazolopyrimidine derivative according to the present invention can reduce dosing frequency because of its long half-life, and therefore, has an advantage to improve the drug compliance of patients suffering from chronical liver diseases.

WO 2006/132460 A1